Relmada Therapeutics, Inc. (RLMD)
3.58
+0.14
(+4.07%)
USD |
NASDAQ |
Oct 30, 16:00
3.595
+0.02
(+0.42%)
After-Hours: 20:00
Relmada Therapeutics Enterprise Value : 164.15M for Oct. 30, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 30, 2026 | 164.15M |
| October 29, 2026 | 149.21M |
| October 28, 2026 | 139.61M |
| October 27, 2026 | 124.68M |
| October 26, 2026 | 126.81M |
| October 23, 2026 | 131.08M |
| October 22, 2026 | 133.21M |
| October 21, 2026 | 124.68M |
| October 20, 2026 | 140.68M |
| October 19, 2026 | 119.35M |
| October 16, 2026 | 112.95M |
| October 15, 2026 | 123.61M |
| October 14, 2026 | 127.88M |
| October 13, 2026 | 140.68M |
| October 12, 2026 | 156.68M |
| October 09, 2026 | 143.88M |
| October 08, 2026 | 120.41M |
| October 07, 2026 | 128.95M |
| October 06, 2026 | 132.15M |
| October 05, 2026 | 153.48M |
| October 02, 2026 | 166.28M |
| October 01, 2026 | 172.68M |
| September 30, 2026 | 184.41M |
| September 29, 2026 | 180.15M |
| September 28, 2026 | 186.55M |
| Date | Value |
|---|---|
| September 25, 2026 | 190.81M |
| September 24, 2026 | 188.68M |
| September 23, 2026 | 185.48M |
| September 22, 2026 | 234.55M |
| September 21, 2026 | 226.02M |
| September 18, 2026 | 221.75M |
| September 17, 2026 | 230.28M |
| September 16, 2026 | 232.42M |
| September 15, 2026 | 255.88M |
| September 14, 2026 | 255.88M |
| September 11, 2026 | 264.42M |
| September 10, 2026 | 216.41M |
| September 09, 2026 | 218.55M |
| September 08, 2026 | 235.62M |
| September 04, 2026 | 254.82M |
| September 03, 2026 | 248.42M |
| September 02, 2026 | 266.55M |
| September 01, 2026 | 258.02M |
| August 31, 2026 | 247.35M |
| August 28, 2026 | 244.15M |
| August 27, 2026 | 264.42M |
| August 26, 2026 | 267.62M |
| August 25, 2026 | 271.88M |
| August 24, 2026 | 270.82M |
| August 21, 2026 | 276.15M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.889B |
| Corcept Therapeutics, Inc. | 8.456B |
| Veru, Inc. | 14.23M |
| Johnson & Johnson | 685.05B |
| Eli Lilly & Co. | 1.379T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -12.91M |
| Total Expenses (Quarterly) | 12.91M |
| EPS Diluted (Quarterly) | -0.1149 |
| Earnings Yield | -25.98% |
| Normalized Earnings Yield | -25.92 |